Jim Chanos, the founder and president of Kynikos Associates, is a long-time short-seller of Tesla stock. Tesla stock has fallen 17.5% in the last year.
Flotek Industries (FTK) is 0.04% of the iShares Core S&P Small-Cap ETF (IJR). IJR increased 8% in the past year, versus a 56% decrease in FTK’s stock price during the period.
San Francisco–based biopharmaceutical company Nektar Therapeutics (NKTR) develops drug candidates that make use of its advanced polymer conjugate technology platforms.
Biotech firm Spectrum Pharmaceuticals (SPPI) develops oncology and hematology drug products. SPPI generates ~90% of its revenues from the US market, and ~10% of its revenues come from Europe.
In 3Q17, Nektar Therapeutics (NKTR) reported revenues of $152.9 million, a YoY rise of 320.7%. The sudden spurt is mainly due to the upfront payment of $150 million from Eli Lilly.
Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.
In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.
On July 3, 2017, Flotek’s (FTK) implied volatility was ~58%. Since its 1Q17 earnings were announced on May 3, 2017, FTK’s implied volatility has remained unchanged.
Flotek’s management expects an optimum recovery in energy reservoirs by upstream operators, which has already started to push demand for FTK’s technology.
What does Flotek Industries’ management think? Flotek Industries’ (FTK) management believes the company resisted energy market weakness through steady performance in the energy chemistry segment. In the company’s 3Q16 conference call, Flotek Industries CEO John Chisholm stated that “we feel fortunate that our focus on high-end value added technology, especially in our energy chemistry segment […]
Flotek Industries’ net debt-to-trailing 12 month adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) rose from 2Q15 to 2Q16.
Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees.
Richard Bernstein advises against trying to time the markets. What happens more often than not is that retail investors end up buying high and selling low—the opposite of what they should be doing.
Buffett said that it has been a terrible mistake to bet against America, not only for the past 240 years but even now. He believes that America’s emphasis on innovation and strength in commerce will continue to provide strong gains for its people.
Education Realty Trust is a self-managed and self-administered equity REIT. The main objective of the company is to develop, acquire, own, and manage student housing properties.
Fortunately for Century Aluminum, its leverage ratios are currently much lower than other companies in this space. CENX has $123 million in cash that should help it manage its operations over the next few quarters
Century Aluminum’s (CENX) consolidated shipments in 3Q15 were down 1% as compared to 2Q15. In 4Q14, CENX had acquired Alcoa’s stake in the Mt. Holly smelter.
